Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
BIVV's Cash-to-Debt is ranked higher than
63% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. BIVV: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
BIVV' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.56
BIVV's Equity-to-Asset is ranked lower than
65% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BIVV: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
BIVV' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.56  Med: 0.78 Max: 0.81
Current: 0.56
0.56
0.81
Interest Coverage No Debt
BIVV's Interest Coverage is ranked higher than
51% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIVV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
BIVV' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 11.68
Beneish M-Score: -2.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 38.27
BIVV's Operating Margin % is ranked higher than
95% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. BIVV: 38.27 )
Ranked among companies with meaningful Operating Margin % only.
BIVV' s Operating Margin % Range Over the Past 10 Years
Min: -267.93  Med: 25.22 Max: 38.27
Current: 38.27
-267.93
38.27
Net Margin % 30.43
BIVV's Net Margin % is ranked higher than
94% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. BIVV: 30.43 )
Ranked among companies with meaningful Net Margin % only.
BIVV' s Net Margin % Range Over the Past 10 Years
Min: -268.08  Med: 24.91 Max: 49.54
Current: 30.43
-268.08
49.54
ROE % 51.22
BIVV's ROE % is ranked higher than
98% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. BIVV: 51.22 )
Ranked among companies with meaningful ROE % only.
BIVV' s ROE % Range Over the Past 10 Years
Min: -245.27  Med: 40.3 Max: 92.46
Current: 51.22
-245.27
92.46
ROA % 29.84
BIVV's ROA % is ranked higher than
98% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. BIVV: 29.84 )
Ranked among companies with meaningful ROA % only.
BIVV' s ROA % Range Over the Past 10 Years
Min: -191.45  Med: 27.88 Max: 72.81
Current: 29.84
-191.45
72.81
ROC (Joel Greenblatt) % 292.90
BIVV's ROC (Joel Greenblatt) % is ranked higher than
97% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. BIVV: 292.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIVV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -274.99  Med: 53.7 Max: 292.9
Current: 292.9
-274.99
292.9
3-Year Revenue Growth Rate 105.30
BIVV's 3-Year Revenue Growth Rate is ranked higher than
95% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. BIVV: 105.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIVV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 52.65 Max: 105.3
Current: 105.3
0
105.3
GuruFocus has detected 3 Warning Signs with Bioverativ Inc BIVV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIVV's 30-Y Financials

Financials (Next Earnings Date: 2018-08-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

BIVV Guru Trades in Q2 2017

Louis Moore Bacon 25,000 sh (New)
Joel Greenblatt 227,377 sh (+106.88%)
Columbia Wanger 589,054 sh (+24.54%)
Eaton Vance Worldwide Health Sciences Fund 134,621 sh (+74.19%)
Jeff Auxier 24,179 sh (unchged)
First Eagle Investment Sold Out
Richard Snow Sold Out
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 11,531 sh (-0.10%)
PRIMECAP Management 7,699,738 sh (-0.53%)
Jeff Ubben 7,163,892 sh (-15.49%)
» More
Q3 2017

BIVV Guru Trades in Q3 2017

Paul Tudor Jones 203,015 sh (New)
David Dreman 300 sh (New)
Jim Simons 804,800 sh (New)
Steven Cohen 141,000 sh (New)
Joel Greenblatt 386,990 sh (+70.20%)
Columbia Wanger 609,942 sh (+3.55%)
Eaton Vance Worldwide Health Sciences Fund 134,621 sh (unchged)
Louis Moore Bacon Sold Out
Jeff Auxier 24,167 sh (-0.05%)
PRIMECAP Management 7,642,976 sh (-0.74%)
Ronald Muhlenkamp 11,137 sh (-3.42%)
Jeff Ubben 1,270,619 sh (-82.26%)
» More
Q4 2017

BIVV Guru Trades in Q4 2017

Pioneer Investments 16,755 sh (New)
Columbia Wanger 1,032,033 sh (+69.20%)
Steven Cohen 194,500 sh (+37.94%)
Jeff Auxier 24,172 sh (+0.02%)
Paul Tudor Jones Sold Out
Jeff Ubben Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Ronald Muhlenkamp 11,127 sh (-0.09%)
PRIMECAP Management 7,622,324 sh (-0.27%)
Joel Greenblatt 152,666 sh (-60.55%)
Jim Simons 291,200 sh (-63.82%)
David Dreman 10 sh (-96.67%)
» More
Q1 2018

BIVV Guru Trades in Q1 2018

Ronald Muhlenkamp Sold Out
David Dreman Sold Out
PRIMECAP Management Sold Out
Jeff Auxier Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Pioneer Investments Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BIVV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2018-03-31 Sold Out 0.12%$54.95 - $104.98 $ 104.9815%0
Ronald Muhlenkamp 2018-03-31 Sold Out 0.18%$54.95 - $104.98 $ 104.9815%0
David Dreman 2018-03-31 Sold Out $54.95 - $104.98 $ 104.9815%0
Joel Greenblatt 2017-12-31 Reduce -60.55%0.19%$49.01 - $60.22 $ 104.9892%152,666
Ronald Muhlenkamp 2017-12-31 Reduce -0.09%$49.01 - $60.22 $ 104.9892%11,127
David Dreman 2017-12-31 Reduce -96.67%0.01%$49.01 - $60.22 $ 104.9892%10
Joel Greenblatt 2017-09-30 Add 70.20%0.13%$54.78 - $63.72 $ 104.9879%386,990
Ronald Muhlenkamp 2017-09-30 Reduce -3.42%0.01%$54.78 - $63.72 $ 104.9879%11,137
David Dreman 2017-09-30 New Buy0.01%$54.78 - $63.72 $ 104.9879%300
Joel Greenblatt 2017-06-30 Add 106.88%0.1%$51.9 - $62.57 $ 104.9885%227,377
Ronald Muhlenkamp 2017-06-30 Reduce -0.10%$51.9 - $62.57 $ 104.9885%11,531
First Eagle Investment 2017-06-30 Sold Out 0.02%$51.9 - $62.57 $ 104.9885%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:HKSE:02269, NAS:JUNO, OCSE:GEN, NAS:BLUE, NAS:JAZZ, NAS:ALKS, NAS:ALNY, NAS:BMRN, NAS:SGEN, OCSE:NZYM B, XBRU:UCB, SZSE:002252, NAS:NBIX, NAS:BGNE, NAS:SAGE, NAS:EXEL, XKRX:215600, HKSE:01177, NAS:NKTR, NAS:IONS » details
Traded in other countries:50B.Germany, BIVV.Mexico,
Headquarter Location:USA
Bioverativ Inc is a global biotechnology company which focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Its products includes Eloctate and Alprolix.

Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.

Top Ranked Articles about Bioverativ Inc

Jeff Auxier's Top Trades in 1st Quarter 'The big profits go to the intelligent, careful and patient investor, not to the reckless and overeager speculator,' he reminds shareholders
Guru investor Jeff Auxier (Trades, Portfolio)’s firm, Auxier Asset Management, initiated three new positions in the early months of the year. Read more...
5 Companies Hit 52-Week Highs Recently, multiple companies have all managed to reach yearly highs
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs. Read more...
5 Companies Reach 52-Week Highs Recently, 5 companies have managed to achieve yearly highs
According to GuruFocus list of 52-week highs, these guru stocks have reached their 52-week highs. Read more...
5 Companies Hit 52-Week Highs As of late, multiple companies have all managed to reach yearly highs
According to GuruFocus' list of 52-week highs, these guru stocks have reached their 52-week highs. Read more...
Where Are Biotech Industry Vets Taking a Seat at the Table Right Now? Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets
Within the last 12 months we have seen some of the largest biopharma buyouts in history. Last year, Gilead Sciences Inc. (NASDAQ:GILD) acquired Kite Pharma Inc. (NASDAQ:KITE) in a deal that was valued at nearly $12 billion! This year we’ve already begun to see the trend continue after Bioverativ Inc. (NASDAQ:BIVV) was acquired by French biotech company, Sanofi SA ADR (NYSE:SNY) in an $11.6 billion deal. Furthermore, announcements that Celgene Corp. (NASDAQ:CELG) would acquire Juno Therapeutics Inc. (NASDAQ:JUNO) and AbbVie, Inc. (NYSE:ABBV) could seek deals to build onto or complement its early-stage Alzheimer's disease pipeline have kept the fire piping hot for biotech buyouts. With this in mind, there’s no doubt that the future could hold even larger deals in the biopharma space considering immense advancements that this sector is seeing right now. Read more...
IPG Photonics Set to Join S&P 500; ALLETE and LendingTree to Join S&P MidCap 400; New York Mortgage Trust, Global Net Lease and Finisar to Join S&P SmallCap 600
5 Companies Reach 52-Week Highs Multiple companies have achieved recently yearly highs
IMS Health Holdings Inc. (NYSE:IMS) reached the 52-week high of $31.34 Read more...
Five Companies Hit 52-Week Highs Multiple companies have all managed to reach yearly highs recently
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-week highs. Read more...
WeissLaw LLP Investigates Bioverativ Inc. Acquisition
SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Bioverativ, Inc. - BIVV

Ratios

vs
industry
vs
history
PE Ratio 32.01
BIVV's PE Ratio is ranked lower than
53% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. BIVV: 32.01 )
Ranked among companies with meaningful PE Ratio only.
BIVV' s PE Ratio Range Over the Past 10 Years
Min: 10.78  Med: 14.37 Max: 32.01
Current: 32.01
10.78
32.01
Forward PE Ratio 24.45
BIVV's Forward PE Ratio is ranked higher than
51% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. BIVV: 24.45 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 32.01
BIVV's PE Ratio without NRI is ranked lower than
52% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. BIVV: 32.01 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIVV' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.78  Med: 14.37 Max: 32.01
Current: 32.01
10.78
32.01
PB Ratio 12.65
BIVV's PB Ratio is ranked lower than
83% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. BIVV: 12.65 )
Ranked among companies with meaningful PB Ratio only.
BIVV' s PB Ratio Range Over the Past 10 Years
Min: 5.95  Med: 9.35 Max: 12.65
Current: 12.65
5.95
12.65
PS Ratio 9.75
BIVV's PS Ratio is ranked higher than
55% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIVV: 9.75 )
Ranked among companies with meaningful PS Ratio only.
BIVV' s PS Ratio Range Over the Past 10 Years
Min: 4.58  Med: 5.98 Max: 9.75
Current: 9.75
4.58
9.75
Price-to-Free-Cash-Flow 19.73
BIVV's Price-to-Free-Cash-Flow is ranked higher than
66% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. BIVV: 19.73 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIVV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.28  Med: 17.05 Max: 19.92
Current: 19.73
9.28
19.92
Price-to-Operating-Cash-Flow 19.29
BIVV's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. BIVV: 19.29 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIVV' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.07  Med: 15.94 Max: 19.29
Current: 19.29
9.07
19.29
EV-to-EBIT 24.43
BIVV's EV-to-EBIT is ranked higher than
50% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. BIVV: 24.43 )
Ranked among companies with meaningful EV-to-EBIT only.
BIVV' s EV-to-EBIT Range Over the Past 10 Years
Min: 11  Med: 15.8 Max: 24.6
Current: 24.43
11
24.6
EV-to-EBITDA 23.66
BIVV's EV-to-EBITDA is ranked lower than
54% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. BIVV: 23.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIVV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.7  Med: 14.2 Max: 23.8
Current: 23.66
10.7
23.8
EV-to-Revenue 9.35
BIVV's EV-to-Revenue is ranked higher than
59% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. BIVV: 9.35 )
Ranked among companies with meaningful EV-to-Revenue only.
BIVV' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.2  Med: 5.8 Max: 9.4
Current: 9.35
4.2
9.4
Current Ratio 2.00
BIVV's Current Ratio is ranked lower than
74% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. BIVV: 2.00 )
Ranked among companies with meaningful Current Ratio only.
BIVV' s Current Ratio Range Over the Past 10 Years
Min: 2  Med: 4.23 Max: 5.82
Current: 2
2
5.82
Quick Ratio 1.89
BIVV's Quick Ratio is ranked lower than
72% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. BIVV: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
BIVV' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.67 Max: 1.89
Current: 1.89
1.06
1.89
Days Inventory 134.33
BIVV's Days Inventory is ranked lower than
53% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. BIVV: 134.33 )
Ranked among companies with meaningful Days Inventory only.
BIVV' s Days Inventory Range Over the Past 10 Years
Min: 134.33  Med: 684.04 Max: 1488.29
Current: 134.33
134.33
1488.29
Days Sales Outstanding 59.16
BIVV's Days Sales Outstanding is ranked higher than
54% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. BIVV: 59.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIVV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.16  Med: 61.48 Max: 183.04
Current: 59.16
59.16
183.04
Days Payable 34.07
BIVV's Days Payable is ranked lower than
68% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. BIVV: 34.07 )
Ranked among companies with meaningful Days Payable only.
BIVV' s Days Payable Range Over the Past 10 Years
Min: 19.49  Med: 54.3 Max: 143.05
Current: 34.07
19.49
143.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.10
BIVV's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. BIVV: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIVV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1  Med: -0.05 Max: 0
Current: -0.1
-0.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 198.08
BIVV's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. BIVV: 198.08 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BIVV' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 101.74  Med: 101.74 Max: 198.08
Current: 198.08
101.74
198.08
Price-to-Tangible-Book 124.98
BIVV's Price-to-Tangible-Book is ranked lower than
98% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. BIVV: 124.98 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIVV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 64.11  Med: 64.11 Max: 124.98
Current: 124.98
64.11
124.98
Price-to-Median-PS-Value 1.63
BIVV's Price-to-Median-PS-Value is ranked lower than
72% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. BIVV: 1.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIVV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.84  Med: 0.84 Max: 1.64
Current: 1.63
0.84
1.64
Price-to-Graham-Number 13.32
BIVV's Price-to-Graham-Number is ranked lower than
94% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.76 vs. BIVV: 13.32 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIVV' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 6.84  Med: 6.84 Max: 13.32
Current: 13.32
6.84
13.32
Earnings Yield (Greenblatt) % 4.09
BIVV's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. BIVV: 4.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIVV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.09  Med: 6.35 Max: 9.1
Current: 4.09
4.09
9.1

More Statistics

Revenue (TTM) (Mil) $1,168.50
EPS (TTM) $ 3.28
52-Week Range $48.14 - 105.01
Shares Outstanding (Mil)108.22

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 1,359 1,414 1,390
EBIT (Mil $)
EBITDA (Mil $) 519 604 606
EPS ($) 3.75 4.30 4.25
EPS without NRI ($) 3.75 4.30 4.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.12%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}